{"id":637067,"date":"2023-02-06T19:48:02","date_gmt":"2023-02-06T19:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=637067"},"modified":"2023-02-06T19:48:02","modified_gmt":"2023-02-06T19:48:02","slug":"major-depressive-disorder-clinical-trials-emerging-therapies-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/major-depressive-disorder-clinical-trials-emerging-therapies-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight_637067.html","title":{"rendered":"Major Depressive Disorder Clinical Trials, Emerging Therapies, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1675679685.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Major Depressive Disorder Clinical Trials, Emerging Therapies, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1675679685.jpeg\" alt=\"Major Depressive Disorder Clinical Trials, Emerging Therapies, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cMajor Depressive Disorder \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&#8216;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Major Depressive Disorder Pipeline Insight 2023<\/a>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Major Depressive Disorder therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Major Depressive Disorder pipeline domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Major Depressive Disorder Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 75+ Major Depressive Disorder pipeline therapies are in various stages of development, and their anticipated acceptance in the Major Depressive Disorder market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Major Depressive Disorder companies developing novel drug candidates to improve the Major Depressive Disorder treatment landscape include <strong>Sage Therapeutics, Relmada Therapeutics, Inc, Minerva Sciences, Sirtsei Pharmaceuticals, Inc., Small Pharma, BioLite Inc<\/strong>, and others.<\/li>\n<li>Promising Major Depressive Disorder pipeline therapies in various stages of development include <strong>SAGE-217, REL-1017, Seltorexant, SP-624, SPL026, PDC-1421<\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of MDD isn&rsquo;t known.&nbsp;<\/p>\n<p style=\"text-align: justify;\">However, there are several factors that can increase the risk of developing the condition. Symptoms must occur for a period of 2 or more weeks and at least one symptom is either depressed mood or loss of interest or pleasure. MDD is often treated with medication and psychotherapy. Some lifestyle adjustments can also help ease certain symptoms.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample page report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">major depressive disorder treatment algorithm and diagnosis<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>REL-1017: Relmada Therapeutics, Inc<\/strong><\/p>\n<p style=\"text-align: justify;\">REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about the emerging Major Depressive Disorder drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Major Depressive Disorder Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Sage Therapeutics&nbsp;<\/li>\n<li>Relmada Therapeutics, Inc<\/li>\n<li>Minerva Sciences&nbsp;<\/li>\n<li>Sirtsei Pharmaceuticals, Inc.<\/li>\n<li>Small Pharma<\/li>\n<li>BioLite Inc<\/li>\n<li>And others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>SAGE-217<\/li>\n<li>REL-1017<\/li>\n<li>Seltorexant<\/li>\n<li>SP-624<\/li>\n<li>SPL026<\/li>\n<li>PDC-1421<\/li>\n<li>And others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>By development stage<\/li>\n<li>By product type<\/li>\n<li>By route of administration<\/li>\n<li>By molecule type<\/li>\n<li>By MOA type&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Major Depressive Disorder Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage:&nbsp;Global&nbsp;<\/strong><\/li>\n<li><strong>Key Major Depressive Disorder Companies:<\/strong> Sage Therapeutics, Relmada Therapeutics, Inc, Minerva Sciences, Sirtsei Pharmaceuticals, Inc., Small Pharma, BioLite Inc, and others<\/li>\n<li><strong>Key Major Depressive Disorder Pipeline Therapies:<\/strong> SAGE-217, REL-1017, Seltorexant, SP-624, SPL026, PDC-1421, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about the Major Depressive Disorder treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Major Depressive Disorder Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Asthma Diagnostic Devices Market<\/li>\n<li>Chronic Obstructive Pulmonary Disease Treatment Devices Market<\/li>\n<li>Airway Management Devices Market<\/li>\n<li>Cough Assist Devices Market<\/li>\n<li>Pulse Oximeters Market<\/li>\n<li>Hemodialysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Contact Us<\/strong><\/p>\n<p style=\"text-align: justify;\">Kritika Rehani<\/p>\n<p style=\"text-align: justify;\">info@delveinsight.com&nbsp;<\/p>\n<p style=\"text-align: justify;\">+1(919)321-6187&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=major-depressive-disorder-clinical-trials-emerging-therapies-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=major-depressive-disorder-clinical-trials-emerging-therapies-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s, \u201cMajor Depressive Disorder \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/major-depressive-disorder-clinical-trials-emerging-therapies-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight_637067.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-637067","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=637067"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637067\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=637067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=637067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=637067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}